All Articles

Findings of a randomized study suggest that follow-up CT scans may not be needed every 3 to 6 months during the first 2 years after surgery for patients with non–small cell lung cancer (NSCLC).

In this issue of the Journal of Oncology Navigation & Survivorship (JONS), we are proud to present the evidence-based research abstracts that have been accepted to the Eighth Annual Navigation & Survivorship Conference of the Academy of Oncology Nurse & Patient Navigators (AONN+).

Today there are ever-increasing challenges surrounding breast cancer care. The ongoing disparities in delivering cancer care continue to impact our nation as a whole, and, more importantly, for both patients and providers in our local communities.

Currently, pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States. However, with the lack of early detection tests and treatment options, it is estimated that PC may move to the second leading cause of cancer death in the United States by 2020 or even earlier.

The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists.

According to Morgan, “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.”

The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care.

Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.

The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually.

The Cancer Support Community (CSC) has designed a patient/provider discussion tool for patients with chronic myeloid leukemia (CML).